Hyphens Pharma International Limited (SGX:1J5)

Market Cap	103.47M
Revenue (ttm)	185.32M
Net Income (ttm)	6.46M
Shares Out	308.88M
EPS (ttm)	0.02
PE Ratio	16.38
Forward PE	8.82
Dividend	0.02 (4.48%)
Ex-Dividend Date	May 7, 2025

Volume	145,900
Average Volume	135,395
Open	0.3350
Previous Close	0.3350
Day's Range	0.3350 - 0.3350
52-Week Range	0.2600 - 0.3450
Beta	-0.10
RSI	54.62
Earnings Date	Aug 14, 2025

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Specialty pharma principals; Proprietary brands; and Medical hypermart and digital segments. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products through...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 474
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 1J5

Financial Performance

In 2024, SGXC:1J5's revenue was 195.42 million, an increase of 14.55% compared to the previous year's 170.60 million. Earnings were 10.19 million, an increase of 18.98%.